Welcome to day 1 of the J.P. Morgan Healthcare Conference, the industry's most significant dealmaking event each year.  | For ...

Asterasis, a beauty medical device corporation, announced on the 15th that it recorded a subscription competition rate of ...

Johnson & Johnson acquires Intra-Cellular Therapies for $14.6 billion. The biggest driver was the rights Caplyta which has ...

Bristol Myers Squibb plans to release initial late-stage trial data on Cobenfy in Alzheimer's-related psychosis during the ...

Key Takeaways JNJ will buy Intra-Cellular Therapies, producer of a drug for bipolar disorder, for $14.6 billion. Eli Lilly ...

S&P Global Ratings placed Johnson & Johnson on CreditWatch with negative implications, citing its nearly $15 billion deal to acquire mental-illness drug developer Intra-Cellular Therapies.

Detailed price information for Johnson & Johnson (JNJ-N) from The Globe and Mail including charting and trades.

Johnson & Johnson is starting the year off strong with a $14.6 billion acquisition of the biopharma firm Intra-Cellular Therapies — best known for its blockbuster drug Caplyta. The deal was announced ...

Johnson & Johnson (J&J) is in discussions to acquire Intra-Cellular Therapies in the biggest biotech transaction in more than a year.

“There are differences between the evolution of those with bipolar 1 disorder compared with those with bipolar ... supplement options you might consider incorporating into your treatment plan for ...

What we need to remember is that these mental health conditions require separate diagnoses, and each has different treatment plans to address the problematic ... Biobehavioral Reviews, up to 1 in 16 ...

An emerging field of genetics promises to let parents choose the “healthiest” baby.